The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.45
Bid: 3.40
Ask: 3.50
Change: 0.15 (4.55%)
Spread: 0.10 (2.941%)
Open: 3.40
High: 3.45
Low: 3.33
Prev. Close: 3.30
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - The Allergy Therapeutics Plc

20 Jun 2023 09:57

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

River and Mercantile Asset Management PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

The Allergy Therapeutics PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

19/06/2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

0.1P ORDINARY

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

25,700,000

3.7844%

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

25,700,000

3.7844%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

0.1p Ordinary

Sell

3,000,000

0.014092

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

20 June 2023

Contact name:

Operational Compliance Department

River and Mercantile

Raela Tomas

Telephone number*:

+44 20 3327 5653

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230620035004/en/

Copyright Business Wire 2023

Date   Source Headline
13th Jul 20167:00 amRNSTrading Update
8th Jul 20167:00 amRNSResults of mite immunotherapy Acarovac PlusT
27th Jun 20167:00 amRNSFindings from mEEC dose range finding study G204
13th Jun 20167:00 amRNSAllergy hosts Satellite Symposium at EAACI
10th Jun 20167:00 amRNSAppointment of Finance Director
9th May 20167:00 amRNSPositive Phase II Data
23rd Mar 20169:02 amRNSIssue of equity in respect of options exercise
17th Mar 20167:00 amRNSBoard Change
11th Mar 20164:36 pmRNSGrant of Options under Long Term Incentive Plan
8th Mar 20167:00 amRNSInterim Results for the six months ended 31/12/15
24th Feb 20167:30 amRNSHardman & Co Research Report: Development Progress
23rd Feb 20167:00 amRNSNotice of Interim Results
18th Feb 20167:00 amRNSPatient enrolment completed in US Phase IIb study
13th Jan 20167:00 amRNSTrading Update
7th Dec 20157:00 amRNSUS Phase II study for GrassMATAMPL initiated
2nd Dec 20153:47 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSPQBirch204 Phase II study update
27th Nov 20153:21 pmRNSHolding(s) in Company
25th Nov 20156:06 pmRNSGrant of Options under Long Term Incentive Plan
18th Nov 201512:23 pmRNSResult of AGM
17th Nov 201512:51 pmRNSResults of Placing
17th Nov 20157:01 amRNSProposed placing to raise up to £12 million
17th Nov 20157:00 amRNSTrading Update
4th Nov 20157:00 amRNSWorld Vaccine Congress Presentation
21st Oct 20152:48 pmRNSHardman & Co issues research report
16th Oct 20157:00 amRNSAnnual Report and Accounts
21st Sep 20157:00 amRNSFinal Results
1st Sep 20157:04 amRNSFirst patient recruited in PQ Birch dose study
10th Aug 20157:00 amRNSKey paper published in the World Allergy Journal
27th Jul 20157:00 amRNSDirector Share Dealings
23rd Jul 20157:00 amRNSNotice of Results and Trading Update
6th Jul 20157:00 amRNSPositive Dust Mite Study Results
2nd Jul 20157:00 amRNSCompany to Host Key Allergy Conference
25th Jun 20157:00 amRNSCompany to resume US clinical programme
5th Jun 201510:59 amRNSAcquisition of Alerpharma S.A.
9th Apr 20155:51 pmRNSHolding(s) in Company
8th Apr 20153:47 pmRNSHolding(s) in Company
1st Apr 20153:20 pmRNSHolding(s) in Company
30th Mar 201511:27 amRNSResult of General Meeting and Issue of Equity
10th Mar 20157:03 amRNSIssue of Equity
2nd Mar 20157:00 amRNSHalf Yearly Report
30th Jan 20153:58 pmRNSHolding(s) in Company
12th Jan 20157:00 amRNSTrading Update
16th Dec 20142:00 pmRNSChange of Adviser
19th Nov 20141:16 pmRNSResult of AGM
18th Nov 20147:00 amRNSAppointment of a Non-Executive Director
5th Nov 20147:00 amRNSGrant of Options
4th Nov 20147:00 amRNSAppointment of Head of Clinical Science
23rd Oct 20143:19 pmRNSAnnual Report and Accounts
8th Oct 20147:44 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.